FindTrial
Sign In

PF-06463922

DRUG5 trials

Sponsors

Pfizer

Conditions

ALK-positive Non Small Cell Lung Cancer (NSCLC) and ROS1-positive NSCLCHealthyNon-Small Cell Lung Cancer

Phase 1

A Study Of PF-06463922 An ALK/ROS1 Inhibitor In Patients With Advanced Non Small Cell Lung Cancer With Specific Molecular Alterations
CompletedNCT01970865
PfizerALK-positive Non Small Cell Lung Cancer (NSCLC) and ROS1-positive NSCLC
Start: 2014-01-08End: 2023-05-24Updated: 2024-08-12
PPI And Food Effect Study For PF-06463922 In Healthy Volunteers
CompletedNCT02569554
PfizerHealthy
Start: 2015-12-31End: 2016-04-30Updated: 2016-05-17
Study to Evaluate Safety, Efficacy, Pharmacokinetics And Pharmacodynamics Of Avelumab In Combination With Either Crizotinib Or PF-06463922 In Patients With NSCLC. (Javelin Lung 101)
TerminatedNCT02584634
PfizerNon-Small Cell Lung Cancer
Start: 2015-12-18End: 2022-07-13Updated: 2023-07-07
A Study To Evaluate The Effect Of Rifampin On Pharmacokinetics Of PF-06463922 In Healthy Volunteers
CompletedNCT02804399
PfizerHealthy
Start: 2016-07-31End: 2016-10-31Updated: 2019-01-25
A Study To Evaluate The Effect Of Itraconazole On Pharmacokinetics Of PF-06463922 In Healthy Volunteers
CompletedNCT02838264
PfizerHealthy
Start: 2016-08-16End: 2017-05-03Updated: 2017-05-15

Related Papers

Final Overall Survival and Long-Term Safety of Lorlatinib in Patients With ALK-Positive NSCLC From the Pivotal Phase 2 Study: A Brief Report
Journal of Thoracic Oncology2024-11-2213 citations
Avelumab in Combination With Lorlatinib or Crizotinib in Patients With Previously Treated Advanced NSCLC: Phase 1b/2 Results From the JAVELIN Lung 101 Trial.
2024-05-1612 citations
Updated Efficacy and Safety of Lorlatinib in a Phase 2 Study in Chinese Patients With Previously Treated Advanced ALK-Positive Non-small Cell Lung Cancer.
2024-04-301 citations
Cost-effectiveness of first-line versus second-line use of brigatinib followed by lorlatinib in patients with ALK-positive non-small cell lung cancer
Frontiers in Public Health2024-02-15
Evaluation of the Effect of Lorlatinib on CYP2B6, CYP2C9, UGT, and P-Glycoprotein Substrates in Patients with Advanced Non-Small Cell Lung Cancer
Clinical Pharmacokinetics2023-12-116 citations
Factors Associated With Developing Neurocognitive Adverse Events in Patients Receiving Lorlatinib After Progression on Other Targeted Therapies.
2022-09-2921 citations
Efficacy and safety of lorlatinib in Asian and non-Asian patients with ALK-positive advanced non-small cell lung cancer: Subgroup analysis of a global phase 2 trial.
2022-05-2313 citations
Continuation of Lorlatinib in ALK-Positive NSCLC Beyond Progressive Disease.
2022-01-1013 citations
Phase 1 Study Evaluating the Effects of the Proton Pump Inhibitor Rabeprazole and Food on the Pharmacokinetics of Lorlatinib in Healthy Participants
Clinical Pharmacology in Drug Development2021-07-206 citations
Lorlatinib Exposure‐Response Analyses for Safety and Efficacy in a Phase I/II Trial to Support Benefit–Risk Assessment in Non‐Small Cell Lung Cancer
Clinical Pharmacology & Therapeutics2021-05-1125 citations
Pharmacokinetics of Lorlatinib After Single and Multiple Dosing in Patients with Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer: Results from a Global Phase I/II Study.
2021-05-0324 citations
The Effect of Modafinil on the Safety and Pharmacokinetics of Lorlatinib: A Phase I Study in Healthy Participants
Clinical Pharmacokinetics2021-05-039 citations
Intracranial and extracranial efficacy of lorlatinib in patients with ALK-positive non-small-cell lung cancer previously treated with second-generation ALK TKIs.
2021-02-2477 citations
Abstract CT025: Impact of the EML4-ALK fusion variant on the efficacy of lorlatinib in patients (pts) with ALK-positive advanced non-small cell lung cancer (NSCLC)
Cancer Research2020-08-153 citations
Lorlatinib in previously treated anaplastic lymphoma kinase‐rearranged non–small cell lung cancer: Japanese subgroup analysis of a global study
Cancer Science2020-07-1816 citations
Impact of lorlatinib on patient-reported outcomes in patients with advanced ALK-positive or ROS1-positive non-small cell lung cancer.
2020-03-1014 citations
Brain Penetration of Lorlatinib: Cumulative Incidences of CNS and Non-CNS Progression with Lorlatinib in Patients with Previously Treated ALK-Positive Non-Small-Cell Lung Cancer.
2020-02-0185 citations
The Effect of Rifampin on the Pharmacokinetics and Safety of Lorlatinib: Results of a Phase One, Open-Label, Crossover Study in Healthy Participants.
2019-12-2029 citations
The effect of itraconazole on the pharmacokinetics of lorlatinib: results of a phase I, open-label, crossover study in healthy participants.
2019-11-1419 citations
Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1-2 trial.
2019-10-25266 citations

13 more papers not shown